When was Miroculus founded?

Miroculus was founded in 2014 and raised its 1st funding round within a year of its incorporation.

Where is Miroculus located?

Miroculus is headquartered in San Francisco, United States.

How many employees does Miroculus have?

As of Aug 31, 2026, the latest employee count at Miroculus is 13.

Is Miroculus a funded company?

Miroculus is a funded company, having raised a total of $48.4M across 4 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on 2014.

When was the latest funding round of Miroculus?

Miroculus' latest funding was a $***** Series B round on Feb 25, 2021, with participation from 2 investors.

Where does Miroculus rank among its competitors?

Miroculus ranks 13th amongst 173 active competitors, of which 53 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was Mirvie, which secured $23.7M in Jul, 2025.

Who are the top competitors of Miroculus?

Miroculus' top competitors include Geneoscopy, Freenome Health and OncoCyte. Among them, Mirvie secured the most recent funding round in July, 2025.

Miroculus - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of MicroRNA profiling platform to detect genes in the sample. The product Miro Canvas based on microfluidic technology automates experimental workflows on a cartridge and provides minimally invasive molecular testing.

Website: miroculus.com
Social
Email ID: *****@miroculus.com

Key Metrics

Founded Year

2014

Location

San Francisco, United States

Stage

Acquired

Total Funding

$48.4M in 4 rounds

Latest Funding Round

Series B, Feb 25, 2021, $*****

Investors

Nazca & 12 more

Ranked

13^th among 173 active competitors

Employee Count

13 as on Aug 31, 2026

Investment & Acquisitions

Kapplex

Similar Companies

Geneoscopy & 167 more

Exit Details

Acquired by Integra Biosciences (Mar 16, 2023)

View Miroculus' full profile

Miroculus got acquired by Integra Biosciences on Mar 16, 2023.

Click here to take a look at Miroculus's acquisition in detail

Miroculus has raised a total funding of $48.4M over 4 rounds. Its first funding round was on 2014. Its latest funding round was a Series B round on Feb 25, 2021 for $*****. 2 investors participated in its latest round. Miroculus has 13 institutional investors.

Here is the list of recent funding rounds of Miroculus:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 25, 2021	1846405	Series B	2540657	1123079	9957660	9162631
Feb 25, 2019	6750942	Series B	6860875	8721976	8653725	1720423
Apr 21, 2015	8494479	Seed	9292520	8136135	9571213	9314483

Access funding benchmarks and valuations. Sign up today!

View details of Miroculus's funding rounds and investors

The founders of Miroculus is Fay Christodoulou.

Here are the details of Miroculus' key team members:

Fay Christodoulou: Co-Founder & CSO of Miroculus.

View details of Miroculus's Founder profiles and Board Members

Miroculus' employee count trend

Miroculus has 13 employees as of Aug 26. Here is Miroculus's employee count trend over the years:

Uncover Miroculus' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Miroculus include Geneoscopy, Freenome Health and OncoCyte. Here is the list of Top 10 competitors of Miroculus, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Geneoscopy 2015, St. Louis (United States), Series C	Developer of non-invasive biomarker tests for colorectal cancer	$219M	LightChain Capital, Cultivation Capital & 18 others	67/100
2nd	Freenome Health 2014, United States, Series E	Provider of a deep learning platform for detecting circulating cancer-related markers	$1.35B	Perceptive Advisors, RA Capital Management ... & 65 others	66/100
3rd	OncoCyte 2009, Irvine (United States), Public	Developer of non-invasive diagnostic tests solutions for the treatment of cancer	$15.3M	Geode Capital, Connor, Clark & Lunn Financial Group ... & 5 others	66/100
4th	Mirvie 2019, San Francisco (United States), Series B	Provider of non-invasive diagnostic tests for pregnant women	$114M	Decheng Capital, Khosla Ventures & 10 others	59/100
5th	Biological Dynamics 2010, San Diego (United States), Series C	Provider of molecular diagnostics plaform	$67.6M	Alexandria, Heritage Group & 6 others	58/100
6th	Codiak BioSciences 2015, Cambridge (United States), Public	Developer of exosome-based drugs and diagnostics for cancer treatment	$168M	Arch Venture Partners, Flagship Pioneering ... & 10 others	57/100
7th	Fluidic Analytics 2013, Cambridge (United Kingdom), Series C	Develops microfluidic-based tools for protein characterization	$40.5M	Draper Esprit, IQ Capital & 23 others	55/100
8th	Mursla 2017, London (United Kingdom), Seed	Provider of diagnostic device for cancer detection	$547K	Future Fund, TA Ventures & 26 others	55/100
9th	InterVenn 2017, San Francisco (United States), Series C	Provider of an AI-based clinical decision supporting tool for cancer detection and drug development	$251M	Genoa Ventures, SoftBank Group & 12 others	53/100
10th	Diagnoplex 2005, Lausanne (Switzerland), Acquired	Molecular diagnostics for colorectal cancer.	$9.68M	NeoMed, Novartis Venture Fund & 2 others	53/100
13th	Miroculus 2014, San Francisco (United States), Acquired	Developer of MicroRNA profiling platform to detect genes in the sample	$48.4M	Section 32, Humboldt Fund & 11 others	50/100